Enliven Therapeutics stock price target raised to $56 by H.C. Wainwright
#Enliven Therapeutics #stock price target #H.C. Wainwright #$56 #biotech #financial analysis #investment
📌 Key Takeaways
- H.C. Wainwright increased Enliven Therapeutics' stock price target to $56.
- The adjustment reflects analyst optimism about the company's prospects.
- The target suggests potential growth from the current trading price.
- The move is part of ongoing financial analysis of the biotech sector.
🏷️ Themes
Stock Analysis, Biotechnology
Entity Intersection Graph
No entity connections available yet for this article.